Outset Medical (NASDAQ:OM) General Counsel Sells $47,687.68 in Stock

Outset Medical, Inc. (NASDAQ:OM) General Counsel John Brottem sold 9,314 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total transaction of $47,687.68. Following the completion of the sale, the general counsel owned 36,957 shares in the company, valued at $189,219.84. This represents a 20.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Outset Medical Stock Up 3.0%

Outset Medical stock traded up $0.15 during mid-day trading on Wednesday, hitting $5.20. 256,678 shares of the company’s stock were exchanged, compared to its average volume of 1,737,004. The company’s 50 day simple moving average is $4.34 and its 200-day simple moving average is $11.07. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.77 and a current ratio of 7.09. Outset Medical, Inc. has a fifty-two week low of $3.10 and a fifty-two week high of $21.98.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Alyeska Investment Group L.P. increased its stake in Outset Medical by 10.2% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock worth $22,798,000 after acquiring an additional 150,000 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of Outset Medical by 34.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 508,414 shares of the company’s stock worth $1,886,000 after purchasing an additional 131,381 shares in the last quarter. Pura Vida Investments LLC grew its holdings in shares of Outset Medical by 8,482.4% during the 2nd quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock worth $8,243,000 after purchasing an additional 424,120 shares in the last quarter. Millennium Management LLC increased its position in shares of Outset Medical by 165.8% in the third quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock worth $5,950,000 after purchasing an additional 262,874 shares during the period. Finally, Geode Capital Management LLC raised its stake in Outset Medical by 955.9% in the second quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock valued at $7,984,000 after purchasing an additional 376,196 shares in the last quarter.

Analyst Upgrades and Downgrades

OM has been the topic of several analyst reports. Royal Bank Of Canada reiterated a “sector perform” rating and set a $7.00 target price on shares of Outset Medical in a report on Wednesday, December 17th. Wall Street Zen downgraded shares of Outset Medical from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Stifel Nicolaus dropped their price target on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 29th. Finally, BTIG Research restated a “buy” rating and set a $17.00 price objective on shares of Outset Medical in a research note on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Outset Medical currently has an average rating of “Moderate Buy” and a consensus price target of $10.67.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.